ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics is a clinical-stage biotechnology firm dedicated to developing novel therapies for immune inflammatory diseases, with a focus on advanced monoclonal antibody treatments. ImmuneWalk Therapeutics specializes in creating therapies for immune inflammatory conditions and was established in 2023. The firm is based in Pearl River, US. The company has completed one deal, raising USD 7.

00 mn in a Seed funding round in May 2025. Founded by individuals with extensive experience in biotechnology, ImmuneWalk is focused on innovative therapeutic development. ImmuneWalk Therapeutics focuses on the development of innovative therapies to address immune inflammatory indications, with a core product offering centered around IW-601. This proprietary monoclonal antibody is engineered to inhibit the migration of monocytes to inflamed tissues, thereby presenting a novel treatment paradigm in anti-inflammatory therapies.

IW-601 has demonstrated disease-modifying activity in preclinical models for conditions such as Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Metabolic dysfunction-associated steatohepatitis (MASH). Currently, IW-601 is undergoing evaluation in the POINTGUARD Phase 1 clinical trial, which has successfully completed its Single Ascending Dose stage. The company is focused on serving both prevalent and rare inflammatory conditions, targeting markets that include North America and Europe, aimed at healthcare providers and patients seeking advanced treatment options. ImmuneWalk Therapeutics operates on a clinical-stage model, with revenue generation primarily linked to its flagship product, IW-601, as it progresses through clinical trials and towards commercialization.

The transaction structure is centered on partnerships with healthcare institutions and potential collaborations with pharmaceutical companies for further development and distribution of its therapies. Revenue may be derived from milestone payments associated with clinical trial advancements, as well as future product sales contingent upon successful market entry. The company’s focus on B2B relationships with healthcare providers and collaboration with research institutions underscores its commitment to impactful therapeutic solutions. Pricing strategies for IW-601 will align with industry standards for monoclonal antibody therapies, reflecting the product's unique value proposition in the treatment of inflammatory diseases.

ImmuneWalk Therapeutics plans to utilize the recent funding of USD 7. 00 mn raised in May 2025 to advance the clinical development of IW-601, which will include ongoing early-stage studies and preparation for future trials targeting immune-inflammatory diseases. The company aims to expand its presence in North America and Europe, with specific strategies for market entry that align with its product development timeline.